Abstract
The fact that the phosphatidylinositol 3 kinase (PI3K) signaling pathway is one of the most frequently deregulated signaling networks has triggered intensive efforts in the development of PI3K pathway inhibitors. However, recent clinical trial data have shown only limited activity of PI3K inhibitors at tolerated doses. Thus, there is an urgent need to identify rational combination therapy to improve the efficacy of PI3K-targeted cancer treatment. In this study, we investigated if dietary compound ellagic acid (EA) could improve the therapeutic efficacy of PI3K inhibitor GDC-0941 in breast cancer. Specifically, using a panel of breast cancer cell lines, we showed that combined use of EA and GDC-0941 significantly inhibited cell growth under attached and detached conditions, blocked migration and invasion in vitro as well as tumor initiation and metastasis in vivo. Furthermore, we found that EA promoted apoptosis and further reduced AKT/mTOR activation in GDC-0941- treated breast cancer cells. Together, our data suggest that EA may be a safe and effective agent to boost the efficacy of PI3K-directed breast cancer therapy and that such drug combination may merit further clinical investigation.
Keywords: Breast cancer, combination therapy, ellagic acid, GDC-0941, PI3K, targeted therapy.
Current Molecular Medicine
Title:Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Volume: 15 Issue: 5
Author(s): L. Shi, X. Gao, X. Li, N. Jiang, F. Luo, C. Gu, M. Chen, H. Cheng and P. Liu
Affiliation:
Keywords: Breast cancer, combination therapy, ellagic acid, GDC-0941, PI3K, targeted therapy.
Abstract: The fact that the phosphatidylinositol 3 kinase (PI3K) signaling pathway is one of the most frequently deregulated signaling networks has triggered intensive efforts in the development of PI3K pathway inhibitors. However, recent clinical trial data have shown only limited activity of PI3K inhibitors at tolerated doses. Thus, there is an urgent need to identify rational combination therapy to improve the efficacy of PI3K-targeted cancer treatment. In this study, we investigated if dietary compound ellagic acid (EA) could improve the therapeutic efficacy of PI3K inhibitor GDC-0941 in breast cancer. Specifically, using a panel of breast cancer cell lines, we showed that combined use of EA and GDC-0941 significantly inhibited cell growth under attached and detached conditions, blocked migration and invasion in vitro as well as tumor initiation and metastasis in vivo. Furthermore, we found that EA promoted apoptosis and further reduced AKT/mTOR activation in GDC-0941- treated breast cancer cells. Together, our data suggest that EA may be a safe and effective agent to boost the efficacy of PI3K-directed breast cancer therapy and that such drug combination may merit further clinical investigation.
Export Options
About this article
Cite this article as:
Shi L., Gao X., Li X., Jiang N., Luo F., Gu C., Chen M., Cheng H. and Liu P., Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells, Current Molecular Medicine 2015; 15 (5) . https://dx.doi.org/10.2174/1566524015666150505161046
DOI https://dx.doi.org/10.2174/1566524015666150505161046 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Current Cancer Drug Targets Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells
Medicinal Chemistry Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets Magnetic Materials for the Selective Analysis of Peptide and Protein Biomarkers
Current Medicinal Chemistry Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design A Review on Melatonin’s Effects in Cancer: Potential Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism Evaluation of Effect of Ligand on Cellular Internalization: A Comparative Study of Nanoparticles and Multifunctional Nanoparticles on MDA-MB-231 Cells
Current Nanoscience MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases
Current Drug Delivery Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Pyrazole Derivatives as Antitumor, Anti-Inflammatory and Antibacterial Agents
Mini-Reviews in Medicinal Chemistry